Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Wet age-related macular degeneration

Wet age-related macular degeneration

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Wet age-related macular degeneration

9 trials tracked for Wet age-related macular degeneration: 4 in phase 3 or 4.

9Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 5
  1. Phase 4 Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Completed
  2. Phase 4 Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed
  3. Phase 3 A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) Completed
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Completed
  5. Phase 2 Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) Completed
  6. Phase 2 INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Completed
Show 3 more trials
  1. Phase 2 Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration Completed
  2. Phase 2 Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration Completed
  3. Phase 2 Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Engineered nanobodies offer programmable platform to overcome limitations of conventional antibodies in angiogenic diseases
Allergy & Immunology Sys. Review
Engineered nanobodies offer programmable platform to overcome limitations of conventional antibodies in angiogenic diseases Engineered nanobodies may offer better ways to treat solid tumors
This systematic review examines engineered nanobodies targeting angiogenesis-related pathways for solid tumors and other conditions like wet…
Tiny engineered proteins called nanobodies could overcome the limitations of standard treatments for solid tumors and other blood vessel-rel…
Frontiers Aug 21, 2026